2905 Amprenavir Amprenavir is only found in individuals that have used or taken this drug. It is a protease inhibitor used to treat HIV infection.Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. 161814-49-9 65016 C25H35N3O6S 505.224660 White powder. 4.91e-02 g/L Rapidly absorbed after oral administration in HIV-1-infected patients with a time to peak concentration (T_max) typically between 1 and 2 hours after a single oral dose. The absolute oral bioavailability of amprenavir in humans has not been established. Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Hepatic. Amprenavir is metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system. The 2 major metabolites result from oxidation of the tetrahydrofuran and aniline moieties. Glucuronide conjugates of oxidized metabolites have been identified as minor metabolites in urine and feces. Half Life: 7.1-10.6 hours No indication of carcinogenicity to humans (not listed by IARC). For the treatment of HIV-1 infection in combination with other antiretroviral agents. If overdosage occurs, the patient should be monitored for evidence of toxicity and standard supportive treatment applied as necessary. (L1712) 2009-07-21T20:27:27Z 2014-12-24T20:25:52Z Amprenavir C08086 2684 Amprenavir DB00701 478 true [H][C@@](O)(CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1)[C@]([H])(CC1=CC=CC=C1)N=C(O)O[C@@]1([H])CCOC1 C25H35N3O6S InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1 InChIKey=YMARZQAQMVYCKC-OEMFJLHTSA-N 505.627 505.224656557 Exogenous Solid HMDB14839 CHEMBL116 58532 <p><a href="http://www.drugsyn.org/Amprenavir.htm">DrugSyn.org</a></p>